• Explore /
  • Poster
  • / ARTISTRY-7: A phase 3, multicenter study of nemvaleukin alfa in combination with pembrolizumab versus chemotherapy in patients (pts) with platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer.

ARTISTRY-7: A phase 3, multicenter study of nemvaleukin alfa in combination with pembrolizumab versus chemotherapy in patients (pts) with platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer.

Abstract Video & Slides Poster

Authors

null

Thomas J. Herzog

University of Cincinnati, University of Cincinnati Cancer Institute, Cincinnati, OH

Thomas J. Herzog , Kathleen N. Moore , Panagiotis A. Konstantinopoulos , Lucy Gilbert , John L. Hays , Bradley J. Monk , David M. O'Malley , Jalid Sehouli , Joyce N. Barlin , Julie R. Graham , Monali Desai, MD , Yan Wang , Yangchun Du , Rita P. Dalal , Robert L. Coleman

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2022 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Gynecologic Cancer

Track

Gynecologic Cancer

Sub Track

Ovarian Cancer

Clinical Trial Registration Number

NCT05092360

Citation

J Clin Oncol 40, 2022 (suppl 16; abstr TPS5609)

DOI

10.1200/JCO.2022.40.16_suppl.TPS5609

Abstract #

TPS5609

Poster Bd #

481a

Abstract Disclosures

Similar Posters

First Author: Thomas J. Herzog

First Author: Kathleen N. Moore

First Author: Kathleen N. Moore

First Author: Sarina Anne Piha-Paul